Welcome to our dedicated page for Viridian Therapeutics SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viridian Therapeutics, Inc. filings document a clinical-stage biotechnology company with common stock listed on Nasdaq under VRDN. The company’s Form 8-K disclosures report financial results, Regulation FD clinical updates, corporate presentations, and material agreements, including underwriting arrangements for common stock offerings.
Viridian’s regulatory filings also cover its thyroid eye disease programs, including elegrobart trial disclosures and updates related to veligrotug, as well as cash resources, research and development activity, and financing transactions. Proxy materials document annual meeting matters, director elections, executive compensation, equity plans, and related governance procedures.
Viridian Therapeutics reported positive phase 3 REVEAL-2 topline results for elegrobart, a subcutaneous anti‑IGF‑1R antibody in chronic thyroid eye disease (TED). Elegrobart achieved proptosis responder rates of 50% with every‑4‑week dosing and 54% with every‑8‑week dosing at week 24, versus 15% on placebo, with high statistical significance (p < 0.0001).
The Q4W arm also showed a 61% diplopia responder rate at week 24 compared with 38% on placebo (p = 0.0118). Across both dosing regimens, elegrobart was generally well tolerated, with low placebo‑adjusted rates of hearing impairment and 91% of treated patients completing the full course.
Viridian plans a Biologics License Application (BLA) submission for elegrobart in Q1 2027 and highlights that it is the only subcutaneous program with positive phase 3 data in both active and chronic TED. Veligrotug, its intravenous IGF‑1R antibody, has a PDUFA target action date of June 30, 2026, under Priority Review and Breakthrough Therapy Designation, while cash of $762 million as of March 31, 2026 is described as sufficient, together with anticipated milestones and revenues if approvals occur, to fund current plans through profitability.
Viridian Therapeutics reported positive phase 3 REVEAL-2 topline results for elegrobart, a subcutaneous anti‑IGF‑1R antibody in chronic thyroid eye disease (TED). Elegrobart achieved proptosis responder rates of 50% with every‑4‑week dosing and 54% with every‑8‑week dosing at week 24, versus 15% on placebo, with high statistical significance (p < 0.0001).
The Q4W arm also showed a 61% diplopia responder rate at week 24 compared with 38% on placebo (p = 0.0118). Across both dosing regimens, elegrobart was generally well tolerated, with low placebo‑adjusted rates of hearing impairment and 91% of treated patients completing the full course.
Viridian plans a Biologics License Application (BLA) submission for elegrobart in Q1 2027 and highlights that it is the only subcutaneous program with positive phase 3 data in both active and chronic TED. Veligrotug, its intravenous IGF‑1R antibody, has a PDUFA target action date of June 30, 2026, under Priority Review and Breakthrough Therapy Designation, while cash of $762 million as of March 31, 2026 is described as sufficient, together with anticipated milestones and revenues if approvals occur, to fund current plans through profitability.
Viridian Therapeutics reported positive phase 3 REVEAL-2 topline results for elegrobart, a subcutaneous anti‑IGF‑1R antibody in chronic thyroid eye disease (TED). Elegrobart achieved proptosis responder rates of 50% with every‑4‑week dosing and 54% with every‑8‑week dosing at week 24, versus 15% on placebo, with high statistical significance (p < 0.0001).
The Q4W arm also showed a 61% diplopia responder rate at week 24 compared with 38% on placebo (p = 0.0118). Across both dosing regimens, elegrobart was generally well tolerated, with low placebo‑adjusted rates of hearing impairment and 91% of treated patients completing the full course.
Viridian plans a Biologics License Application (BLA) submission for elegrobart in Q1 2027 and highlights that it is the only subcutaneous program with positive phase 3 data in both active and chronic TED. Veligrotug, its intravenous IGF‑1R antibody, has a PDUFA target action date of June 30, 2026, under Priority Review and Breakthrough Therapy Designation, while cash of $762 million as of March 31, 2026 is described as sufficient, together with anticipated milestones and revenues if approvals occur, to fund current plans through profitability.
Viridian Therapeutics reported a net loss of $104.9 million for the three months ended March 31, 2026, as it continues investing heavily in late‑stage development of therapies for serious and rare diseases. Revenue remained minimal at $0.1 million, while research and development expenses were $77.6 million and selling, general and administrative expenses were $38.7 million, reflecting clinical programs and commercial readiness efforts.
The company is advancing two IGF‑1R antibodies for thyroid eye disease. Veligrotug, an intravenous therapy, has positive phase 3 data in both active and chronic disease, and its biologics license application is under FDA Priority Review with a target action date of June 30, 2026. Subcutaneous elegrobart showed statistically significant proptosis responses in two phase 3 REVEAL trials, and Viridian plans a future BLA submission. As of March 31, 2026, cash, cash equivalents and marketable securities totaled $762.2 million, which management believes will fund planned operations for at least 12 months.
Viridian Therapeutics reported a net loss of $104.9 million for the three months ended March 31, 2026, as it continues investing heavily in late‑stage development of therapies for serious and rare diseases. Revenue remained minimal at $0.1 million, while research and development expenses were $77.6 million and selling, general and administrative expenses were $38.7 million, reflecting clinical programs and commercial readiness efforts.
The company is advancing two IGF‑1R antibodies for thyroid eye disease. Veligrotug, an intravenous therapy, has positive phase 3 data in both active and chronic disease, and its biologics license application is under FDA Priority Review with a target action date of June 30, 2026. Subcutaneous elegrobart showed statistically significant proptosis responses in two phase 3 REVEAL trials, and Viridian plans a future BLA submission. As of March 31, 2026, cash, cash equivalents and marketable securities totaled $762.2 million, which management believes will fund planned operations for at least 12 months.
Viridian Therapeutics reported a net loss of $104.9 million for the three months ended March 31, 2026, as it continues investing heavily in late‑stage development of therapies for serious and rare diseases. Revenue remained minimal at $0.1 million, while research and development expenses were $77.6 million and selling, general and administrative expenses were $38.7 million, reflecting clinical programs and commercial readiness efforts.
The company is advancing two IGF‑1R antibodies for thyroid eye disease. Veligrotug, an intravenous therapy, has positive phase 3 data in both active and chronic disease, and its biologics license application is under FDA Priority Review with a target action date of June 30, 2026. Subcutaneous elegrobart showed statistically significant proptosis responses in two phase 3 REVEAL trials, and Viridian plans a future BLA submission. As of March 31, 2026, cash, cash equivalents and marketable securities totaled $762.2 million, which management believes will fund planned operations for at least 12 months.
Viridian Therapeutics reported first quarter 2026 results and key pipeline milestones. The company is preparing for a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease and has submitted a Marketing Authorization Application in Europe, which was accepted for review.
Subcutaneous elegrobart showed positive topline results in two phase 3 REVEAL trials in active and chronic thyroid eye disease, with a Biologics License Application submission planned in Q1 2027. Viridian ended March 31, 2026 with $762 million in cash, cash equivalents, and short-term investments, generated $141 thousand in total revenues, and recorded a net loss of $104.9 million for the quarter.
Viridian Therapeutics reported first quarter 2026 results and key pipeline milestones. The company is preparing for a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease and has submitted a Marketing Authorization Application in Europe, which was accepted for review.
Subcutaneous elegrobart showed positive topline results in two phase 3 REVEAL trials in active and chronic thyroid eye disease, with a Biologics License Application submission planned in Q1 2027. Viridian ended March 31, 2026 with $762 million in cash, cash equivalents, and short-term investments, generated $141 thousand in total revenues, and recorded a net loss of $104.9 million for the quarter.
Viridian Therapeutics reported first quarter 2026 results and key pipeline milestones. The company is preparing for a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease and has submitted a Marketing Authorization Application in Europe, which was accepted for review.
Subcutaneous elegrobart showed positive topline results in two phase 3 REVEAL trials in active and chronic thyroid eye disease, with a Biologics License Application submission planned in Q1 2027. Viridian ended March 31, 2026 with $762 million in cash, cash equivalents, and short-term investments, generated $141 thousand in total revenues, and recorded a net loss of $104.9 million for the quarter.
Viridian Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 2, 2026 at 2:00 p.m. Eastern Time. Holders of 103,071,889 shares of common stock as of April 7, 2026 can participate and vote.
Stockholders will elect two Class II directors, ratify the selection of KPMG LLP as independent auditor for 2026, cast an advisory vote on executive compensation, and give advisory input on how often “say‑on‑pay” votes should occur, with the Board recommending the one‑year option.
Viridian Therapeutics reported positive topline phase 3 data from its REVEAL-1 trial of subcutaneous elegrobart in active thyroid eye disease (TED). The Q4W dosing arm achieved a proptosis responder rate of 54% versus 18% for placebo at week 24, meeting the primary endpoint with high statistical significance. The Q8W arm reached a 63% proptosis responder rate versus 18% placebo, and complete resolution of diplopia occurred in 51% of Q4W patients versus 16% on placebo. Elegrobart was generally well tolerated, with low placebo-adjusted rates of hearing impairment and adverse events consistent with the anti‑IGF‑1R class.
Viridian is also advancing veligrotug for TED, supported by positive phase 3 THRIVE and THRIVE‑2 results, and targets a PDUFA action date of June 30, 2026 for veligrotug and a planned BLA submission for elegrobart in Q1 2027. The company ended Q4 2025 with $875 million in cash and expects cash, potential near-term royalty milestones, and future revenues from veligrotug and elegrobart, if approved, to fund current plans through profitability.
Viridian Therapeutics Inc ownership disclosure: The Vanguard Group filed an amendment reporting 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment that caused certain Vanguard subsidiaries to report separately from The Vanguard Group, Inc.
The filing lists The Vanguard Group's address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim as Head of Global Fund Administration on 03/27/2026. The submission states Vanguard entities pursue the same investment strategies post‑realignment.
Viridian Therapeutics Chief Financial Officer files an amended insider transaction report reflecting tax-related share withholding. On the corrected Form 4/A, Seth Harmon is shown disposing of 2,031 shares of Viridian common stock on March 3, 2026 at $30.19 per share to cover tax obligations. Following this tax-withholding disposition, he beneficially owns 7,850 shares of common stock. The amendment updates both the number of shares and the price used to satisfy taxes, as well as the resulting total holdings, compared with the initial Form 4 filed on March 4, 2026.
Viridian Therapeutics Chief Operating Officer Thomas W. Beetham filed an amended insider report updating a prior Form 4. The amendment corrects the number of shares and price involved in a tax-withholding disposition of 3,048 shares of common stock at $30.19 per share on a transaction coded “F.”
These shares were withheld to cover taxes, rather than sold in an open-market trade. After this correction and all transactions reported in the original Form 4, Beetham is shown as beneficially owning 13,361 shares of Viridian Therapeutics common stock directly.
Viridian Therapeutics Chief Legal Officer updates prior tax-related share filing. Jennifer Tousignant filed an amended Form 4 to correct the number of shares and price previously reported as disposed to cover taxes. The amendment now shows a tax-withholding disposition of 1,675 shares of common stock at $30.19 per share on March 3, 2026, leaving her with 3,494 shares of Viridian Therapeutics common stock held directly.